Bausch Health Companies Inc - BHC STOCK NEWS

Bausch + Lomb announced the FDA approval of ClearVisc™, a dispersive ophthalmic viscosurgical device (OVD) designed for ophthalmic surgeries, particularly cataract procedures. This innovative OVD provides enhanced corneal protection and visibility, utilizing Sorbitol for superior free radical protection. In clinical trials with 372 subjects, ClearVisc™ demonstrated non-inferior safety and efficacy compared to VISCOAT®, with excellent postoperative outcomes. This approval reflects Bausch + Lomb's commitment to advancing eye health technology and meeting surgical needs.

Bausch Health Companies announced a $100 million debt reduction plan through the redemption of its 7.00% Senior Secured Notes due 2024, scheduled for May 7, 2021. This action follows a previous redemption of $200 million in March 2021. The company aims to utilize cash generated from operations for this redemption, signifying improved liquidity. Bausch Health, focused on health care products across various therapeutic areas, continues to prioritize financial stability amid ongoing uncertainties due to the COVID-19 pandemic.

Bausch Health Companies (NYSE/TSX: BHC) announced a definitive agreement to sell its equity interests in Amoun Pharmaceutical Company for approximately U.S. $740 million. The sale aims to reduce Bausch Health's debt and is expected to close in the first half of 2021, pending regulatory approvals. Amoun is a leading pharmaceutical firm in Egypt known for its branded generics. The transaction includes adjustments for cash generated by Amoun from January 1, 2021, until closing, which will not reflect on Bausch Health's consolidated results.

Bausch Health Companies (NYSE/TSX: BHC) announced the launch of GastroHub for Advanced Practice Providers, a website offering free educational resources for nurse practitioners and physician assistants treating IBS-D and hepatic encephalopathy. Developed with input from healthcare professionals, it includes videos, podcasts, and discussion guides. This initiative follows two other educational platforms launched by Salix Pharmaceuticals within the past year, aiming to enhance patient care in gastrointestinal health.

Bausch Health Companies Inc. (NYSE: BHC) announced a leadership change with Sam Eldessouky succeeding Paul S. Herendeen as CFO, effective June 1, 2021. Herendeen will transition to an advisory role while remaining an executive vice president. Eldessouky, who has been with the company since 2016, brings significant experience, particularly in financial strategy and executing corporate spinoffs. The company also provided an update on its planned spinoff of Bausch + Lomb, indicating ongoing progress in that effort.

Bausch Health Companies Inc. (NYSE/TSX: BHC) presented an update at the Barclays Global Healthcare Conference on March 9, 2021. CEO Joseph C. Papa, along with other executives, detailed the company's current pipeline, particularly focusing on Salix and its rifaximin clinical development efforts. The presentation is accessible via the Investor Relations page on the Bausch Health website, allowing stakeholders to follow developments in this therapeutic area. Forward-looking statements indicate potential risks related to COVID-19 and project timelines, which might impact future performance.

Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched the Clear + Brilliant® Touch laser, enhancing treatment protocols for patients of all ages and skin types. This next-generation system features dual wavelengths, allowing aesthetic providers to offer enhanced treatments in a single session. Notable features include a user-friendly touchscreen and smart charting assistant. As a pioneer in medical aesthetics, Solta Medical continues to advance technologies aimed at improving patient outcomes. The Clear + Brilliant laser has conducted over 2.5 million procedures since its inception.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a plan to reduce its debt by $100 million through the redemption of senior secured notes, utilizing cash generated from operations. This redemption will involve the 7.00% Senior Secured Notes due 2024, with a total of $200 million being redeemed before the first quarter of 2021. The first redemption is scheduled for March 24, 2021, followed by another on March 29, 2021.

The initiative reflects the company's commitment to improving its financial position.

Bausch Health reported Q4 2020 revenues of $2.213 billion and full-year revenues of $8.027 billion, down 7% from 2019 due to COVID-19 impacts, with a GAAP net loss of $153 million for Q4 and $560 million for the entire year. They generated $394 million in cash from operations in Q4, leading to a total of $1.111 billion for the year, allowing for a debt repayment of approximately $900 million. The company is advancing its pipeline and expects 2021 revenues between $8.60 and $8.80 billion.